Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

A phase II clinical trial with single-agent decitabine was conducted in older patients (≥60 years) with previously untreated acute myeloid leukemia (AML) who were not candidates for or who refused intensive chemotherapy. Subjects received low-dose decitabine at 20 mg/m(2) i.v. over 1 h on days 1 to...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Blum, William, Garzon, Ramiro, Klisovic, Rebecca B., Schwind, Sebastian, Walker, Alison, Geyer, Susan, Liu, Shujun, Havelange, Violaine, Becker, Heiko, Schaaf, Larry, Mickle, Jon, Devine, Hollie, Kefauver, Cheryl, Devine, Steven M., Chan, Kenneth K., Heerema, Nyla A., Bloomfield, Clara D., Grever, Michael R., Byrd, John C., Villalona-Calero, Miguel, Croce, Carlo M., Marcucci, Guido
التنسيق: Artigo
اللغة:Inglês
منشور في: National Academy of Sciences 2010
الموضوعات:
Biological Sciences
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC2867720/
https://ncbi.nlm.nih.gov/pubmed/20368434
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1002650107
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة